CN108813163A - A kind of feed addictive and preparation method thereof for treating fish hepatopathy - Google Patents
A kind of feed addictive and preparation method thereof for treating fish hepatopathy Download PDFInfo
- Publication number
- CN108813163A CN108813163A CN201810756337.3A CN201810756337A CN108813163A CN 108813163 A CN108813163 A CN 108813163A CN 201810756337 A CN201810756337 A CN 201810756337A CN 108813163 A CN108813163 A CN 108813163A
- Authority
- CN
- China
- Prior art keywords
- hepatopathy
- feed addictive
- fish
- liver
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000019423 liver disease Diseases 0.000 title claims abstract description 29
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 20
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 20
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 17
- 239000003613 bile acid Substances 0.000 claims abstract description 17
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 10
- 239000004471 Glycine Substances 0.000 claims abstract description 10
- 235000012754 curcumin Nutrition 0.000 claims abstract description 10
- 229940109262 curcumin Drugs 0.000 claims abstract description 10
- 239000004148 curcumin Substances 0.000 claims abstract description 10
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 10
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims abstract description 9
- 229960001627 lamivudine Drugs 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims abstract description 8
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims abstract description 8
- 229960004844 lovastatin Drugs 0.000 claims abstract description 8
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940088598 enzyme Drugs 0.000 claims description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 229920002472 Starch Polymers 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 239000004382 Amylase Substances 0.000 claims description 7
- 108010065511 Amylases Proteins 0.000 claims description 7
- 102000013142 Amylases Human genes 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 claims description 7
- 235000019418 amylase Nutrition 0.000 claims description 7
- 229940106157 cellulase Drugs 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- 108010011619 6-Phytase Proteins 0.000 claims description 2
- 108010001682 Dextranase Proteins 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 2
- 229940040461 lipase Drugs 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 229940085127 phytase Drugs 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 235000019419 proteases Nutrition 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 29
- 244000144972 livestock Species 0.000 abstract description 17
- 241001465754 Metazoa Species 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 230000029087 digestion Effects 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 208000004930 Fatty Liver Diseases 0.000 abstract description 3
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 3
- 208000010706 fatty liver disease Diseases 0.000 abstract description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000011017 operating method Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000000941 bile Anatomy 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 235000019621 digestibility Nutrition 0.000 description 5
- 241000415078 Anemone hepatica Species 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000003445 biliary tract Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000015250 liver sausages Nutrition 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
The invention discloses the feed addictives for the treatment of fish hepatopathy, are calculated by mass percentage, including:Bile acid 1-20%, curcumin 0.1-15%, L-carnitine 0.1-15%, ammonium glycyrrhetate 5-8%, glycine 6-10%, Lamivudine 2-8%, Lovastatin 4-10%, enzyme preparation 0.2-20% and auxiliary material 30.1-60%.Drug prepared by the present invention can effectively prevent the liver diseases such as aquatic livestock fatty liver, liver and gall syndrome, improve survival rate, promote the digestion and absorption of aquatic livestock nutriment, promote animal growth rate, shorten the culture-cycle, reduce feed coefficient, is suitble to the production market demand of feed addictive;The preparation method operating method of the feed addictive for the treatment of fish hepatopathy of the invention is simple, and raw material sources used are stablized, and low in cost, process controllability is strong, can produce the feed addictive of above-mentioned treatment fish hepatopathy.
Description
Technical field
The present invention relates to a kind of technical fields of aquatic products feed additives more particularly to a kind of feed for treating fish hepatopathy to add
Add agent and preparation method thereof.
Background technique
Liver is an organ based on metabolic function, is generating bile, removing toxic substances, blood coagulation, immune, generation energy, water
With very important effect is played in the adjusting of electrolyte, up to 1500 kinds or more of the chemical reaction occurred in liver, because
This is also considered as one huge " chemical plant ".This is because its unique morphology and history structure and Characteristics of Chemical Constituents, are assigned
The complicated and diversified biochemical function of liver is given.
Firstly, the blood supply of liver is very rich, there is arteria hepatica and pylic double blood supply, so that liver is thin
Born of the same parents can not only obtain sufficient oxygen and metabolin from arteria hepatica, but also the largely various battalion by intestinal absorption can be obtained from portal vein
Substance is supported, these are all that the various metabolisms of liver progress have established material base.Secondly, there are vena hepaticas and biliary tract system for liver
It unites dual output channel.Vena hepatica is connected with body circulation, and the metabolite in liver can be transported to its hetero-organization and utilize or be discharged
In vitro;Biliary system is communicated with enteron aisle, the bile of hepatic secretion is discharged into enteron aisle, and some metabolic wastes are discharged simultaneously.
Based on these above-mentioned features, liver is not only in the metabolisms such as sugar, lipid, protein, vitamin, hormone
Central Position, but also the physiological function with bioconversion, secretion and excretion etc., therefore, nourishing and protecting liver just seems outstanding
It is important.In view of the dual channel system of liver, the performance of metabolic function is highly dependent upon enteron aisle, and hepato-enteric circulation is wherein heavy
The ring wanted.
Bile acid in bile is the essential substance of lipid food digestion, and primary bile acid flows into enteron aisle with bile,
While promoting lipid to digest and assimilate, become secondary bile acid by bacterial action in enteron aisle, the bile acid of enteral there are about
95% by intestinal wall reabsorption (including active reabsorption and passive reabsorption), and re-absorbed bile acid trans-portal vein returns liver, warp
After liver cell processing, it is discharged into enteron aisle through biliary tract again together with newly synthesized bile acid, this process is known as the hepato-enteric circulation of bile acid.
The meaning of hepato-enteric circulation is to improve bile availability, the digestion and absorption such as promotion lipid, while can also remove intestines
Road endotoxin safeguards intestinal health.When compromised liver function, enteron aisle is possible to be contaminated;Conversely, intestinal flora loses
It adjusts, is likely to that liver can be poisoned.Therefore, nourishing and protecting liver must have the integrated idea of liver sausage health care, and intestines two are protected in nourishing the liver
Person is inseparable.
Under the conditions of intensive high-density breeding, breeding environment deteriorates, largely using anti-in antibiotic medicine, feedstuff
Presence of trophic factors etc. all can cause to damage to cultivated animals liver and gallbladder, cause to occur becoming main with liver and bladder disease in current cultivation
Want the disease in the liver and gallbladder syndrome of feature.Hepatic disease causes liver function that obstacle occurs, and influences being absorbed and utilized for nutriment, exempts from
Epidemic disease function reduces, anti-stress ability and premunition decline, and then influences aquatic livestock normal growth, and culture efficiency is caused to be damaged
Evil.
Summary of the invention
It is an object of the invention to aiming at the deficiencies in the prior art, provide a kind of liver protecting used for aquiculture
Feed addictive, the feed addictive can be effectively improved hepato-enteric circulation, effectively prevent animal hepatopathy, promote the life of aquatic livestock
Order power and health degree;The preparation method of the feed addictive, preparation process is easy, low production cost, promotes aquatic livestock rouge
Fat metabolism reduces the generation of aquatic products fatty liver, promotes aquatic health growth.
For this purpose, the present invention uses following technical scheme:
A kind of feed addictive for treating fish hepatopathy, is calculated by mass percentage, including:Bile acid 1-20%, curcumin 0.1-
15%, L-carnitine 0.1-15%, ammonium glycyrrhetate 5-8%, glycine 6-10%, Lamivudine 2-8%, Lovastatin 4-10%, enzyme system
Agent 0.2-20% and auxiliary material 30.1-60%.
Feed addictive of the invention can prevent the fatty infiltration of liver of aquatic livestock, enhance its liver function, improve and raise
The absorption efficiency of material promotes aquatic livestock growth and improves its survival rate.
It further explains, bile acid and L-carnitine play an important role in fat metabolism, can effectively prevent to support
Grow animal nutritional disease in the liver and gallbladder;Curcumin can remove the intracorporal free radical of animal with liver protection, cholagogue, protect liver, improve liver
Dirty function promotes bile secretion and the inflammation that diminishes inflammation;Complex enzyme formulation effectively facilitate aquatic livestock to the digestion of nutriment and
It absorbs, reduces the generation of intestinal endotoxin, so that the probability that intestinal endotoxin during hepato-enteric circulation absorbs damage liver is reduced,
Effectively improve feed digestibility;Animal immune function, anti-stress ability and production performance then can be enhanced in multi-vitamins.
Ammonium glycyrrhetate, glycine have anti-inflammatory, protection liver plasma membrane, immunological regulation, antiviral anti-hepatic fibrosis, inhibit liver
Many-sided effect such as cell carcinogenesis, regulating cell apoptosis, anticomplement.ALT, AST are synchronous to improve, and has apparent drop enzyme and removing jaundice to make
With.It is significant to treat hepatitis b curative effect;Lovastatin competitively inhibits the speed limit during cholesterol biosynthesis in vivo
Enzyme HMG-CoA reductase reduces the synthesis of cholesterol, also increases LDL receptor synthesis, mainly
As a result site of action reduces cholesterolemia and low-density lipoprotein cholesterol level in liver.
Above-mentioned each substance rational proportion, synergistic effect can effectively restore the hepar damnification of aquatic livestock and improve immune function
Can, promote the autoimmunity and premunition of aquatic livestock, to reach aquatic livestock normal growth, improves economic benefit of aquaculture
Purpose.
It further explains, the complex enzyme formulation is neutral proteinase, cellulase, phytase, lipase, starch
One or more combinations of enzyme, zytase and dextranase.
The complex enzyme formulation is exogenous enzymes, and addition exogenous enzymes effectively facilitate digestion and suction of the aquatic livestock to nutriment
It receives, reduces the generation of intestinal endotoxin, to reduce the probability that intestinal endotoxin during hepato-enteric circulation absorbs damage liver, have
Effect improves feed digestibility, promotes growth of animals or poultry.
It further explains, the auxiliary material is silica, maltodextrin and starch, accounts for the prevention and treatment hepatopathy feed and adds
The mass percent for adding agent is respectively:Silica 0.1-3%;Maltodextrin 20-37%;Starch 10-20%.
The higher river sand of silicone content can be used in silica, and as the carrier of feed addictive, the main aquatic products that increases is moved
The WeiDongLi Capsule of object helps to digest, and square is applied in poultry feed, while the feed addition by adding the silica
Agent has preferable mobility and anticaking capacity, convenient for the feeding of aquatic livestock.
Malt lake essence is to have with preferable emulsification and thickening effect and promote formed product and inhibit well
The effect of product institutional framework, moldability can be good, can prevent deformation of products from can improve product appearance again, easily be absorbed, extensively
Basic auxiliary material applied to feed product.
The starch is preferably alphalise starch, and is pre-gelatinized starch, facilitates the forming of particle and guarantees certain particle
Hardness and durability increase the stability of aquatic feeds in water, reduce the dust in process, increase caking property, avoid
Feed is easy to loosely in water, so that aquatic livestock ingests and prevent being scattered and being lost for nutriment.These are this field
Known content, no longer additionally repeats.
Preferably, the enzyme preparation is the complex enzyme formulation being made of neutral proteinase, cellulase and amylase.Pass through
Protein digestibility is greatly improved after neutral proteinase is added, after amylase is added, the digestibility of starch, cellulose can be improved
Enzyme can activate the secretion of endogenous enzymes, supplement the deficiency of endogenous enzymes, and be adjusted to endogenous enzymes, guarantee that animal normally digests suction
Function is received, diseases prevention and somatotrophic is played the role of.
Using above-mentioned three kinds of substances as the complex enzyme formulation, it is obviously promoted digestion of the aquatic livestock to nutriment
And absorption, the generation of intestinal endotoxin is reduced, feed digestibility is effectively improved.
A kind of preparation method of the feed addictive of above-mentioned treatment fish hepatopathy, includes the following steps:
(1)By mass percentage, by bile acid 1-20%, curcumin 0.1-15%, L-carnitine 0.1-15%, ammonium glycyrrhetate 5-
8%, glycine 6-10%, Lamivudine 2-8%, Lovastatin 4-10%, enzyme preparation 0.2-20% and auxiliary material 30.1-60% carry out powder
Broken, sieving is mixed, obtains mixture A;
(2)The mixture A is pressed into agent according to prior art technology of preparing, the feed addition for the fish hepatopathy that obtains medical treatment
Agent.
It further explains, the mesh number of the sieving is 24-80 mesh.According to demand prepared by technique, the present invention is to through powder
The requirement of the not clear specification of the partial size of mixed component after broken, as long as component fineness meets the general requirement of feed addictive i.e.
Can, the fineness that the mixture thus crushed is within the scope of 24-80 mesh reaches preparation and requires, and explanation is not developed in details here.
It further explains, the feed addictive of above-mentioned treatment fish hepatopathy is cultivated for aquatic biological.It is controlled by
The feed addictive for treating fish hepatopathy is widely used in aquatic biological cultivation, improves the anti-hepatopathy ability and life of aquatic biological
Power reduces the cost of forage feed, improves the output value of aquatic biological.
It is the characteristics of present invention is according to the hepato-enteric circulation of aquatic livestock, theoretical based on liver sausage one, to bile acid, turmeric
Element, L-carnitine, ammonium glycyrrhetate, glycine, Lamivudine, Lovastatin and complex enzyme formulation each ingredient carry out science and match
5, prepared curcumin can effectively prevent the liver diseases such as aquatic livestock fatty liver, liver and gall syndrome, improve survival rate, promote
Water inlet produces the digestion and absorption of Animal nutrition substance, promotes animal growth rate, shortens the culture-cycle, reduces feed coefficient, is suitble to
The production market demand of feed addictive;The feed addictive is environmentally protective, can be used for large-scale industrial production, for feed
Palatability without any adverse effect.
Simple, the used raw material sources of the preparation method operating method of the feed addictive for the treatment of fish hepatopathy of the invention
Stablize, low in cost, process controllability is strong, can produce the feed addictive of above-mentioned treatment fish hepatopathy.
Specific embodiment
The present invention program is described in detail below by some specific embodiments.Those skilled in the art should manage
Solution, it is following to be embodied as preferred embodiment, only the present invention program is explained, and wherein might have to known skill
The appropriate omission of art, those skilled in the art should understand the present invention in conjunction with the explanation of well-known technique and embodiment.
Embodiment 1:
Weigh bile acid 20kg, curcumin 5kg, L-carnitine 3kg, ammonium glycyrrhetate 5kg, glycine 6kg, Lamivudine 2kg, Lip river
Cut down statin 4kg neutral proteinase 4kg, cellulase 2.5kg, amylase 12.5kg, silica 0.1kg, maltodextrin
36.06kg and α starch 16kg is crushed, sieving(Mesh number is 24-80 mesh), it is mixed, obtains mixture A;According to prior art
The mixture A is pressed into agent by technology of preparing, the feed addictive for the fish hepatopathy that obtains medical treatment.
Embodiment 2:
Weigh bile acid 1kg, curcumin 15kg, L-carnitine 15kg, ammonium glycyrrhetate 6kg, glycine 7kg, Lamivudine 6kg,
Lovastatin 5kg, neutral proteinase 2kg, cellulase 1kg, amylase 6kg, silica 2.5kg, maltodextrin 37kg and α
Starch 20kg is crushed, sieving(Mesh number is 24-80 mesh), it is mixed, obtains mixture A;According to prior art technology of preparing handle
The mixture A is pressed into agent, the feed addictive for the fish hepatopathy that obtains medical treatment.
Embodiment 3:
Weigh bile acid 15kg, curcumin 15kg, L-carnitine 0.1kg, ammonium glycyrrhetate 8kg, glycine 10kg, Lamivudine
8kg, Lovastatin 10kg, neutral proteinase 4kg, cellulase 3kg, amylase 13kg, silica 3kg, maltodextrin
31.9kg and α starch 10kg is crushed, sieving(Mesh number is 24-80 mesh), it is mixed, obtains mixture A;According to prior art system
The mixture A is pressed into agent by standby technology, the feed addictive for the fish hepatopathy that obtains medical treatment.
The above description of the embodiments is intended to facilitate ordinary skill in the art to understand and use the invention.
Person skilled in the art obviously easily can make various modifications to these embodiments, and described herein general
Principle is applied in other embodiments without having to go through creative labor.Therefore, the present invention is not limited to the above embodiments, ability
Field technique personnel announcement according to the present invention, improvement and modification made without departing from the scope of the present invention all should be of the invention
Within protection scope.
Claims (5)
1. a kind of feed addictive for treating fish hepatopathy, which is characterized in that it is calculated by mass percentage, including:Bile acid 1-
20%, curcumin 0.1-15%, L-carnitine 0.1-15%, ammonium glycyrrhetate 5-8%, glycine 6-10%, Lamivudine 2-8%, Lip river are cut down
Statin 4-10%, enzyme preparation 0.2-20% and auxiliary material 30.1-60%;
The enzyme preparation is neutral proteinase, cellulase, phytase, lipase, amylase, zytase and dextranase
One or more combinations;
The auxiliary material is silica, maltodextrin and starch, and the mass percent for accounting for the feed addictive is respectively:Two
Silica 0.1-3%;Maltodextrin 20-37%;Starch 10-20%.
2. the feed addictive for the treatment of fish hepatopathy according to claim 1, which is characterized in that the enzyme preparation is in
Property protease, cellulase and amylase composition complex enzyme formulation.
3. a kind of preparation method for the feed addictive for treating fish hepatopathy, which is characterized in that include the following steps:
(1)By mass percentage, by bile acid 1-20%, curcumin 0.1-15%, L-carnitine 0.1-15%, ammonium glycyrrhetate 5-
8%, glycine 6-10%, Lamivudine 2-8%, Lovastatin 4-10%, enzyme preparation 0.2-20%, silica 0.1-3%, malt paste
Smart 20-37% and starch 10-20% are crushed, and sieving is mixed, obtains mixture A;
(2)The mixture A is pressed into agent, the feed addictive for the fish hepatopathy that obtains medical treatment.
4. the preparation method of the feed addictive for the treatment of fish hepatopathy according to claim 3, which is characterized in that the mistake
The mesh number of sieve is 24-80 mesh.
5. the feed addictive of the treatment fish hepatopathy as described in any one of claim 1-2 is used to aquatic biological to support
It grows.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810756337.3A CN108813163A (en) | 2018-07-12 | 2018-07-12 | A kind of feed addictive and preparation method thereof for treating fish hepatopathy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810756337.3A CN108813163A (en) | 2018-07-12 | 2018-07-12 | A kind of feed addictive and preparation method thereof for treating fish hepatopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108813163A true CN108813163A (en) | 2018-11-16 |
Family
ID=64135851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810756337.3A Withdrawn CN108813163A (en) | 2018-07-12 | 2018-07-12 | A kind of feed addictive and preparation method thereof for treating fish hepatopathy |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108813163A (en) |
-
2018
- 2018-07-12 CN CN201810756337.3A patent/CN108813163A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102450514B (en) | Compound crucian feed and preparation method thereof | |
KR101532922B1 (en) | Biogas residue containing cow feed additive | |
CN106360115A (en) | Feed additive for preventing and treating liver diseases and preparation method of same | |
CN105494179A (en) | Grass carp breeding method | |
CN110338141A (en) | A kind of application of the whole process nonreactive cultural technique scheme in breeding layer chicken | |
CN107439844A (en) | A kind of Penaeus Vannmei special swelling feed | |
CN112294802A (en) | Anti-stress preparation for reducing fry transportation loss and preparation process and use method thereof | |
CN105010832A (en) | Secondary curing producing method for piglet feed | |
CN102870985A (en) | Feed for breast-fed sows and preparation method thereof | |
CN106333137A (en) | Fermentation aroma type antibiotic-free enteritis-preventing ctenopharyngodon idellus young fish formula hard-particle feed and preparation method thereof | |
CN107114324B (en) | Method for breeding quasipaa spinosa by using vitamin-rich yellow mealworms | |
CN105265795A (en) | mutton-sheep feed and preparation method of the mutton-sheep feed | |
CN105028978A (en) | Feed additive capable of improving intestinal function of grass carps and application of feed additive | |
CN109418611A (en) | One kind preventing hepatic feed addictive and preparation method thereof | |
CN104146164A (en) | Cyprinoid feed containing enzymic preparation | |
CN106509344A (en) | Powdery compound feed for preventing young trionyx sinensis from suffering from white abdominal shell disease | |
CN108813163A (en) | A kind of feed addictive and preparation method thereof for treating fish hepatopathy | |
CN111990295B (en) | Method for breeding two batches of channel catfishes in one year | |
JP2005343772A (en) | Composition for organic fertilizer and method of manufacturing organic fertilizer | |
CN108065035A (en) | Porcupine feed and preparation method thereof | |
CN1213667C (en) | High-concentration composite nutrient additive for phosphorus-saving type environment-protecting feed | |
CN106509491A (en) | Compound feed for scophthalmus maximus and preparation method thereof | |
CN106360144A (en) | Green efficient crucian feeding attracting agent and preparation method thereof | |
CN106071361A (en) | A kind of Nano chitosan compound nutritional feedstuff and method for breeding | |
CN105248998A (en) | Fodder for eels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181116 |